WO2008104076A1 - Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée - Google Patents

Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée Download PDF

Info

Publication number
WO2008104076A1
WO2008104076A1 PCT/CA2008/000383 CA2008000383W WO2008104076A1 WO 2008104076 A1 WO2008104076 A1 WO 2008104076A1 CA 2008000383 W CA2008000383 W CA 2008000383W WO 2008104076 A1 WO2008104076 A1 WO 2008104076A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
antimicrobial formulation
antimicrobial
echinacea
silver
Prior art date
Application number
PCT/CA2008/000383
Other languages
English (en)
Inventor
Aroll Exama
Original Assignee
Aroll Exama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aroll Exama filed Critical Aroll Exama
Publication of WO2008104076A1 publication Critical patent/WO2008104076A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention relates to an antimicrobial formulation which comprises a suspension of electrocolloidal silver and Echinacea root extract. More specifically, the invention relates to an antimicrobial formulation comprising a suspension of electrocolloidal silver and Echinacea root in a pharmaceutically acceptable carrier suitable for oral or topical administration and useful for reducing infections and inflammations in a subject.
  • United States Patent No. 7,018,660 entitled “Pharmaceutical compositions and methods for managing skin conditions” relates to a formulation for the cleansing of skin to facilitate the prevention, treatment, and management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea and other inflammatory skin conditions.
  • This product includes an acidic component of a hydroxyacid or tannic acid, or a salt thereof, to exfoliate a portion of the skin, a stabilized hydrogen peroxide to facilitate cleansing of the skin without substantial irritation thereof, and an antimicrobial agent consisting of either an antibacterial agent, an antimicrobial agent, an antiviral agent or a combination thereof, in an amount sufficient to inhibit or reduce microorganisms on the skin.
  • Echinacea is one possible antimicrobial agent that can be used in the present formulation.
  • this formulation limited to dermatological purposes, essentially works as a skin cleansing and sanitizing composition for topical inflammations and is only minimally intended for the treatment of skin infections.
  • the hydrogen peroxide present in the formulation can easily cause skin irritation and discomfort in some subjects.
  • Great Britain Application No. 2,189,394 A entitled "Process for preparing a storage-stable concentrate” consists of a concentrate that can be mixed with hydrogen peroxide to become an effective disinfectant for water, foodstuff, animal feeds, equipment and packages for example.
  • the concentrate includes an inorganic acid with a pH less than 1.6, a silver compound or electrocolloidal silver, an organic acid stabilizer such as tartaric, lactic, salicylic, or citric acid, and optionally gelatin.
  • This invention combines the well-known germicidal effect of silver and hydrogen peroxide in a formulation to cause a synergy of the two disinfecting agents.
  • This formulation is indeed a very efficient antiseptic: however, because it is highly corrosive, its use is limited to disinfection and sterilization for household, industry or hospital purposes and cannot be employed for dermatological means.
  • United States Patent No. 6,231 ,848 entitled “Topical Products as prophylactic of curative agents for bacterial skin infections” relates to topical products to be used as prophylactic or curative agents for bacterial skin infections, containing at least one polymeric complex consisting of hydrogen peroxide, a suitable polymer for the complex formation thereof, possibly another bactericidal compound and possibly a metal salt or a metal colloid.
  • the invention therefore resides in various combinations of these four components destined to provide various degrees of antimicrobial control to the formulation.
  • Electrocolloidal silver is one possible metal colloid used in this invention, providing antibacterial properties to the formulation and the incorporated bactericidal active compound is chosen from aldehydes, alpha- hydroxy carboxylic acids, polyhydroxylated aromatic compounds and hydroxyarylcarboxylic acids.
  • the efficacy of the product depends on the formulation's composition: however, the limited amount of the antimicrobial compound and electrocolloidal metal incorporated in the formulation greatly restricts the antibacterial properties of the final product. Moreover, apart from being limited to dermatological purposes, this formulation can cause skin irritation and discomfort because of its high hydrogen peroxide concentration.
  • United States Patent No. 6,673,374 entitled "Pharmaceutical compositions and methods for managing skin conditions” relates to a pharmaceutical composition and methods for treating inflammatory skin conditions.
  • the composition includes hydrogen peroxide, one or more moisturizing agents and an anti-inflammatory agent.
  • the composition can be used to treat medical conditions such as various types of dermatitis, psoriasis, folliculitis, rosacea, acne, eczema and the like.
  • An antimicrobial agent is typically also present in the formulation in an amount from about 0.01 to 1.5 weight percent.
  • the antimicrobial agent inhibits the formation, and may further reduce, the presence of microbes that cause redness, inflammation, and irritation of the skin.
  • One potential antimicrobial agent is Echinacea: however, the very low proportion of this component in the formulation prevents it from offering high antimicrobial capacities.
  • United States Patent No. 7,115,287 entitled “Topical medicament and method of use” relates to a topical formulation for the treatment of dermatologic conditions in both humans and animals.
  • the medicament includes a mixture of Vitamin A, Vitamin D, Vitamin E, lanolin, petroleum jelly, electrocolloidal silver, tea tree oil, zinc oxide and cornstarch in appropriate proportions. Ingredient proportions may be varied to form an ointment or a paste having a thicker consistency than the ointment.
  • This formulation comprises electrocolloidal silver, which presents advantageous effect of killing bacteria and viruses in affected tissue and functions as an all- natural antibiotic in the formulation.
  • an antimicrobial formulation comprising a suspension of electrocolloidal silver and Echinacea root extract in a pharmaceutically acceptable carrier.
  • the formulation is for oral or topical administration and is used to reduce infections and inflammations in a subject.
  • the pharmaceutically acceptable carrier is an aqueous solution, a cream or a gel.
  • the present invention also provides a dressing wherein the antimicrobial formulation of the invention is dispersed onto a wound- contacting surface of the dressing.
  • the invention also provides a method for producing the antimicrobial formulation, the method comprising the steps of generating electrocolloidal silver in a solution of water and a suspension of Echinacea root extract, and incorporating the admixture in a pharmaceutically acceptable carrier.
  • a method for reducing infections and inflammations in a subject comprising contacting an inflamed and/or infected area with a therapeutically effective amount of antimicrobial formulation.
  • electrolysis designates the two products issued of silver electrolysis, which are silver ions in a solution and metallic silver particles in suspension in a solution.
  • the solution will be considered either as an ionic silver solution when more silver ions are present in the solution (high silver ions / silver particles ratio), or the solution will be considered a colloidal silver solution when silver particles are predominant in the solution (low silver ions / silver particles ratio). All references referred to herein are hereby incorporated by reference.
  • Figure 1 shows the results of the efficacy test of the gel formulation of the present invention against four different types of bacteria. Units are log (CFU/g).
  • Figure 2 shows the results of the efficacy test of the cream formulation of the present invention against 4 different types of bacteria. Units are log (CFU/g).
  • an antimicrobial formulation to reduce infections and inflammations in a subject comprising electrocolloidal silver and Echinacea root extract in suspension in a pharmaceutically acceptable carrier for oral or topical administration.
  • This formulation is highly recommended for the treatment of flu, bronchitis, acne, wounds, otitis, pharyngitis, conjunctivitis, gastroenteritis, traveler's diarrhea, bronchitis, wounds and cuts or any minor infections and/or inflammations.
  • the invention provides both antibacterial and antiviral properties and can be ingested, in its liquid formulation, to treat internal infections and inflammations or either topically applied, in its cream or gel formulation, to treat an affected dermatological tissue.
  • the two main compounds of the formulation are electrocolloidal silver and Echinacea. Being non-toxic and harmless to children in pharmaceutically acceptable doses, those two agents provide high antimicrobial properties to the invention and work in synergy to treat most commonly encountered viral or bacterial-related infections and inflammations in humans. It can be used in two different manners: as a curative treatment for an occurring infection and/or inflammation through repeated daily ingestion of the formulation over a limited period of time or as a preventive treatment through daily intake of a limited amount of the formulation. Moreover, in the case of a viral medical condition, such as the flu, it is recommended to consume the formulation in the first 24 hours following the initial manifestation of symptoms, before the virus becomes uncontrollable.
  • a viral medical condition such as the flu
  • the formulation still allows diminution of the symptoms, shortens the duration of the disease and prevents secondary infections such as bronchitis and pneumonia.
  • the intake of the formulation 24 to 48 hours after the first manifestation of symptom produces a decreased antimicrobial effect but is still effective. It is recommended to ingest the product about 30 minutes before meals and to avoid mixing the product with juices or water as the components of those liquids might interfere with the compounds of the formulation.
  • electrocolloidal silver there are two types of products marketed as electrocolloidal silver, which are silver ions in a solution and metallic silver particles in suspension in a solution. Depending on the solution's ratio of ions to silver particles ratio, the solution will be considered either as an ionic silver solution when more silver ions are present in the solution (high silver ions / silver particles ratio), or the solution will be considered a colloidal silver solution when silver particles are predominant in the solution (low silver ions / silver particles ratio).
  • the electrocolloidal silver is an ionic silver solution.
  • Colloidal silver consists of, more precisely, a suspension of submicroscopic metallic silver particles in an electrocolloidal base, such as demineralized water. It resists sedimentation, diffusion and filtration, thus differing from precipitates.
  • the electrocolloidal silver solution is produced through electrolysis of a silver electrode in a demineralized water filled chamber.
  • This solution has the advantageous effect of killing bacteria and viruses that may be present on or in the affected tissue, therefore allowing it to function in the above formulations as an all-natural antibiotic.
  • the antimicrobial properties of electrocolloidal silver are caused by the presence of Ag + ions in the silver solution. These ions are very reactive and instantly respond to the presence of negatively charged molecules in their surrounding environment. In fact, these ions have the ability to bind in an irreversible manner to enzymes and other active molecules at a cell's surface.
  • silver ions destabilize cell membranes, inactivate proteins and inhibit enzyme action. Therefore, when applied in an area presenting bacteria or virus-caused infections or inflammations, the free silver ions will attach to the membrane of the microbial cells leading to the therapeutic effect.
  • Echinacea plant variety has been popular in both Europe and America as a herbal medicine.
  • Echinacea has been attributed with the ability to boost the body's immune system and ward off infections, particularly the common cold.
  • herbal medicinals can be prepared from the above-ground parts and/or the root.
  • the primary use of Echinacea in the formulation is to accelerate the electrolysis reaction while maintaining the quality and efficacy of the solution.
  • the electrocolloidal silver and Echinacea components both previously described, are the basis of the formulation of the present invention.
  • the other compounds are mainly incorporated to improve the taste and/or efficacy of the formulation, to obtain a desired texture or to add hydrating properties to the product.
  • Stevia extract is used to mask the metallic taste of the formulation.
  • shea butter is used to expand the use of the formulation.
  • Silver is recognized for drying biological tissues when used too frequently, its utilization is therefore limited and is not recommended for chronic conditions such as diabetes or in long- term hospitalized patients.
  • the shea butter comprised in the cream formulation of the present invention compensates for that aspect of the included silver. Indeed, shea butter's biological activities include moisturizing abilities, minor skin ailments healing properties due to its exceptionally large healing fractions (fatty extract) compared to other oils.
  • shea butter will also be useful in preventing contamination by antibiotic resistant bacteria in health care facilities. In fact, in order to be effective, silver must be adsorbed by the surface on which it is applied.
  • liquid or gel formulations are easily washable: therefore, the cream formulation of the present invention will allow silver to be more substantially adsorbed, thereby exerting a longer effect in preventing surface contamination by antibiotic resistant bacteria in health care facilities.
  • the application of a dressing comprising the antimicrobial formulation on the skin of a patient is also a good alternative.
  • the present invention provides an antimicrobial formulation comprising a suspension of electrocolloidal silver and Echinacea root extract in a pharmaceutically acceptable carrier.
  • the formulation is for oral or topical administration and is used to reduce infections and inflammations in a subject.
  • the pharmaceutically acceptable carrier is an aqueous solution, a cream or a gel.
  • Further embodiments include the use of other pharmaceutically acceptable carriers known to one skilled in the art such as ointments, lotions (i.e. an emulsion or a dispersion), solutions, foams, or sprays.
  • the Echinacea root extract may comprise root particles of
  • Echinacea angustotifolia Echinacea atrorubens, Echinacea laevigata, Echinacea pallida, Echinacea paradoxa, Echinacea purpurea, Echinacea sanguinea, Echinacea simulata and Echinacea tennesseensis.
  • the root particles of Echinacea comprise Echinacea root powder, minced Echinacea root or combinations thereof.
  • the electrocolloidal silver comprises a suspended solution of 5 to 30 ppm silver ions.
  • the solution is demineralized and deionized purified water.
  • the electrocolloidal silver comprises a suspended solution of 10 to 12 ppm silver ions.
  • the solution is demineralized and deionized purified water.
  • the pharmaceutically acceptable carrier of the antimicrobial formulation comprises water.
  • the antimicrobial formulation is for oral administration and the pharmaceutically acceptable carrier of the antimicrobial formulation comprises water.
  • Other embodiments include the use of purified water or aqueous solutions.
  • the formulation comprising water as a pharmaceutically acceptable carrier further comprises Stevia leaves extract.
  • the Stevia leaves extract includes powdered Stevia leaves; minced Stevia leaves or combinations thereof.
  • the antimicrobial formulation comprising purified water as a pharmaceutically acceptable carrier further comprises Stevia leaves extract and is for oral administration.
  • the pharmaceutically acceptable carrier of the antimicrobial formulation is a gel.
  • the antimicrobial formulation is for topical administration and the pharmaceutically acceptable carrier of the antimicrobial formulation is a gel.
  • the gel formulation comprises CarbopolTM and a jellifying copolymer.
  • CarbopolTM comprises less than 1% of the formulation.
  • the jellifying copolymer comprises triethanolamine.
  • the triethanolamine comprises less than 1 % of the formulation.
  • the pharmaceutically acceptable carrier of the antimicrobial formulation for topical administration is a cream.
  • the cream formulation for topical administration comprises moisturizing agents, CarbopolTM, jellifying agents or combinations thereof.
  • the moisturizing agent of the cream formulation for topical administration is shea butter, which comprises commercially whitened shea butter; natural shea butter or combinations thereof. In a further embodiment, the moisturizing agent comprises less than 25% of the formulation. Other embodiments include the use of other moisturizing agents known to those skilled in the art.
  • the jellifying agents of the cream formulation comprise propylene glycol, novomer EC-1 , triethanolamine and CarbopolTM. In one embodiment, the jellifying agents comprise less than 2% of the formulation. In another embodiment, the jellifying agents comprise less than 1.5% of the formulation. In a preferred embodiment, the jellifying agents comprise less than 1% of the formulation. Other embodiments include the use of other jellifying agents known to those skilled in the art.
  • the propylene glycol comprises 0,0625 % of the formulation
  • the novomer EC-1 comprises 0,0625 % of the formulation
  • the triethanolamine comprises 0,125 % of the formulation
  • CarbopolTM comprises 0,25 % of the formulation.
  • the present invention also provides a dressing which comprises the antimicrobial formulation of the invention dispersed onto a wound- contacting surface of the dressing.
  • antimicrobial formulation is dispersed onto one or multiple layers of the dressing.
  • the wound-contacting surface of the dressing is made of linen or cotton fiber.
  • additional dressings known in the art such as a patch device, a fixed reservoir, an application chamber, a tape, a sticking plaster, or the like which remains on the skin at the site of application for a prolonged period of time.
  • the invention also provides a method for producing the antimicrobial formulation, the method comprising the steps of generating electrocolloidal silver in a solution of water and a suspension of Echinacea root extract, and incorporating the admixture in a pharmaceutically acceptable carrier.
  • the method for generating electrocolloidal silver comprises passing a current through an electric circuit with a silver electrode in a chamber filled with a solution of deionized water and a suspension of Echinacea root extract.
  • Other embodiments include the use of a solution of deionized and demineralized water.
  • the Echinacea root extract may comprise particles of minced Echinacea root; powdered Echinacea root or combinations thereof.
  • Echinacea root particles are water-brewed before being incorporated in the solution.
  • the Echinacea root particles are water-brewed by infusing 1 g of minced Echinacea root in half a cup of water for 10 minutes.
  • the pharmaceutically acceptable carrier in which the admixture of electrocolloidal silver and Echinacea root is incorporated is a cream.
  • the antimicrobial cream formulation comprises a mix of shea butter, CarbopolTM, jellifying agents and combinations thereof.
  • the shea butter of the formulation comprises commercially whitened shea butter; natural shea butter or combinations thereof.
  • the jellifying agents of the formulation comprising cream as a carrier comprises propylene glycol, novomer EC-1 , triethanolamine and a copolymer of acrylic acid and alkyl acrylate.
  • the jellifying agents are incorporated progressively in the cream after the incorporation of the antimicrobial formulation.
  • a method for reducing infections and inflammations in a subject comprising contacting an inflamed and/or infected area with a therapeutically effective amount of antimicrobial formulation.
  • contacting the inflamed and/or infected problem area is done by oral administration or by topical application of the antimicrobial formulation.
  • the oral administration of the formulation can be done sublingually, by swallowing the formulation or by gargling the formulation.
  • the oral administration of the formulation is to be repeated 3 times a day for a 4-day course when administered within the first 24 hours after the onset of symptoms, or 4 times a day for a 3-5 day course when administered 24-48 hours after the onset of symptoms.
  • Other embodiments include courses of treatment at different frequencies of administration and for shorter or longer periods of time.
  • the topical application of the formulation can be done by direct application of a pharmaceutically acceptable amount of the cream or gel antimicrobial formulation on the skin of a subject or by applying a dressing of the antimicrobial formulation on the skin of a subject.
  • the topical application of the cream/gel antimicrobial formulation or of the dressing is to be repeated 3 times a day for a 4-day course or 4 times a day for a 3-day course for an antibacterial treatment.
  • Other embodiments include courses of treatment at different frequencies of administration and for shorter or longer periods of time.
  • the topical administration of the gel formulation is to be repeated twice a day (morning and night) in cases of acne.
  • the topical application of the dressing is to be repeated once a day or once every two days in cases of light bleeding.
  • the topical administration of the cream formulation is to be repeated whenever the skin is dry.
  • the use of a therapeutically effective amount of the antimicrobial formulation to reduce infections and inflammations in a subject.
  • the use of the formulation comprises contacting an inflamed and/or infected area with a therapeutically effective amount of the oral, gel or cream antimicrobial formulation.
  • contacting the inflamed and/or infected area is done by oral administration or by topical application.
  • use of the antimicrobial formulation by oral administration can be done sublingually, by swallowing the formulation or by gargling the formulation.
  • the oral administration of the formulation is to be repeated 3 times a day for a 4-day course when administered within the first 24 hours after the onset of symptoms or 4 times a day for a 3 to 5-day course when administered 24 to 48 hours after the onset of symptoms.
  • Other embodiments include courses of treatment at different frequencies of administration and for shorter or longer periods of time.
  • the topical application can be done by direct application of a pharmaceutically acceptable amount of the cream or gel antimicrobial formulation on the skin of a subject or by applying a dressing of the antimicrobial formulation on the skin of a subject.
  • the topical application of the cream/gel antimicrobial formulation is to be repeated 3 times a day for a 4-day course or 4 times a day for a 3-day course for an antibacterial treatment.
  • Other embodiments include courses of treatment at different frequencies of administration and for shorter or longer periods of time.
  • the topical application of the dressing is to be repeated twice a day in cases of acne, whenever the skin is dry or once a day or once every two days in cases of light bleeding.
  • Electrocolloidal silver is obtained through the use of current passing through an electric circuit comprising a silver electrode in a chamber filled with a solution of purified (deionized and demineralized) water. Indeed, an electric current is passed across the silver electrode, which is immersed in deionised water: as the current passes, metallic silver (Ag 0 ) migrates from the electrode into the water and converts to silver ions (Ag + ), therefore creating electrocolloidal silver.
  • metallic silver Ag 0
  • silver migrates from the electrode into the water and converts to silver ions (Ag + )
  • silver ions Ag +
  • previously water-brewed minced Echinacea root particles or Echinacea root powder, as well as Stevia Leaves extract, as minced leaves or powdered leaves are incorporated in the solution of purified water before the start of the electrolysis.
  • the minced Echinacea root particles are water-brewed by infusing 1 g of minced Echinacea root particle in half a cup of boiling water for 10 minutes
  • the liquid formulation of the invention is ingested in a 5 ml dosage, ingested sublingually or by gargling, 3 times a day for a 4-day course when administered within the first 24 hours after the onset of symptoms. Ingestion of a total of 60 ml of the formulation normally gets rid of all the symptoms. In case of high temperature or fever, a 5 ml oral dose should be repeated every hour until temperature comes back to normal or until the fever disappears. After a drop in temperature and/or fever, administration of a 5ml dose should be repeated 4 times a day. Ingestion of a total 100 ml of the formulation normally gets rid of all the symptoms. In case of otitis, fill both ears with the liquid and maintain for 3 minutes while administering the formulation as indicated. This formulation should not be mixed with water or juice.
  • Table 1a Results of the treatment of various medical conditions in 10 subjects (Canada) with the liquid formulation of electrocolloidal silver and Echinacea root.
  • Table 1b Results of the treatment of various medical conditions in 19 subjects (Switzerland) with the liquid formulation of electrocolloidal silver and Echinacea root.
  • the gel formulation is made starting from the electrocolloidal silver and Echinacea root solution.
  • the electrolysis of a silver electrode in a deionised-water filled chamber allows production of electrocolloidal silver.
  • the solution of deionised water of the chamber also comprises a suspension of Echinacea root powder, or water-brewed minced Echinacea root, before the launch of the reaction.
  • the minced Echinacea root particles are water-brewed by infusing 1 g of Echinacea root particles in half a cup of boiling water for 10 minutes.
  • CarbopolTM and a jellifying copolymer are incorporated in the formulation following the end of the electrolysis.
  • the CarbopolTM compound is in fact a combination of acrylic acid and alkyl acrylate, available in a powder-like form.
  • the jellifying copolymer which in one embodiment is triethanolamine, allows a modification of the solution's structure in order to create a very stable and malleable gel, whereas CarbopolTM is responsible for thickening the solution.
  • CarbopolTM and the jellifying copolymer should not represent more than 1 % of the total formulation.
  • the produced gel is stable at room temperature for up to two years.
  • the gel formulation of the invention should be delicately applied on the affected area.
  • Figure 1 shows the results of an efficacy test against 4 bacterial strains chosen on the basis of their resistance to certain antibiotics (methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus aeruginosa and Clostridium difficile). A strong reduction in the number of bacterial cells was observed after 10 minutes for each bacterial strain (between 3.98 and 5.30 log CFU/g).
  • the gel formulation allows a quick recovery of the skin's superficial infections and inflammations by simply rubbing the affected area with the gel formulation.
  • the gel formulation should be applied twice a day (morning and night) in cases of acne.
  • Table 2 Results of the treatment of topical infections and inflammations with the gel formulation of electrocolloidal silver and Echinacea root.
  • Table 3 shows the results of microbial inhibition challenge test performed according to the US pharmacopoeia protocol using 5 microorganisms. After a contact time of 24 hours, a reduction in the microbial load between 1.49 and 3.06 log CFU/g (depending on the microbial species) can be observed. This is followed by a gradual reduction in the number of microbial cells up to the end of the 28 day experimental time. On day 28, no microbial growth was detected in the samples. This inhibition was complete since day 7 for S. aureus, A. niger and C. albicans and on day 14 for P. aeruginosa.
  • Table 3 Results of the microbial inhibition (challenge test) (log) by the gel formulation of electrocolloidal silver and Echinacea root.
  • Preparation of cream formulation As previously detained, the basis of this formulation resides in a solution of electrocolloidal silver and Echinacea root.
  • the electrocolloidal silver is produced by electrolysis of a silver electrode in a deionised water filled chamber.
  • minced Echinacea root or Echinacea root powder is incorporated in the solution prior to the start of the chemical reaction. If minced Echinacea root is used, the particles are water-brewed by infusing 1 g of Echinacea in half a cup of boiling water for 10 minutes.
  • CarbopolTM for thickening the formulation
  • shea butter in order to grant hydrating properties to the product
  • jellifying agents to obtain the desired consistency.
  • These compounds are mixed in a specific order: first, CarbopolTM and shea butter are mixed together (Phase 1) in order to prevent shea butter to blend directly with electrocolloidal silver and produce silver proteinate, a compound having the tendency to precipitate.
  • the second step comprises mixing the electrocolloidal silver and Echinacea root solution with the rest of the CarbopolTM to incorporate, the CarbopolTM reacting with the silver and preventing it from reacting with the shea butter (Phase 2).
  • Phase 1 and Phase 2 solutions are blended in and the jellifying agents are progressively incorporated, first propylene glycol, then novomER EC-1 and finally triethanolamine. Posoloqy.
  • the cream formulation of the invention should be delicately applied on the affected area.
  • Figure 2 shows the results of an efficacy test against 4 bacterial strains chosen on the basis of their resistance to certain antibiotics (methicillin resistant staphylococcus aureus, vancomycin resistant enterococcus aeruginosa and Clostridium difficile). A strong reduction in the number of bacterial cells was observed after 10 minutes for each bacterial strain (between 2.22 and 5.79 log CFU/g).
  • Table 4 Results of the microbial inhibition (challenge test) (log CFU/g) by the cream formulation of electrocolloidal silver and Echinacea root.

Abstract

La présente invention concerne une préparation antimicrobienne comprenant de l'argent électro-colloïdal et un extrait de racine d'échinacée en suspension. La préparation antimicrobienne peut être administrée par voie orale ou topique pour réduire les infections et les inflammations chez un sujet. L'invention concerne également une méthode destinée à la production de cette préparation antimicrobienne, consistant à obtenir de l'argent électro-colloïdal dans une solution d'eau et une suspension d'extrait de racine d'échinacée, puis à introduire le mélange dans un excipient de qualité pharmaceutique. L'invention concerne également des préparations orales et des préparations sous forme de gel ou de crème.
PCT/CA2008/000383 2007-03-01 2008-02-28 Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée WO2008104076A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89235507P 2007-03-01 2007-03-01
US60/892,355 2007-03-01

Publications (1)

Publication Number Publication Date
WO2008104076A1 true WO2008104076A1 (fr) 2008-09-04

Family

ID=39720820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/000383 WO2008104076A1 (fr) 2007-03-01 2008-02-28 Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée

Country Status (1)

Country Link
WO (1) WO2008104076A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920855B1 (en) * 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
CN105601861A (zh) * 2016-02-23 2016-05-25 同光（江苏）信息科技有限公司 一种有机硅改性水性聚氨酯树脂的合成方法
JP2020512409A (ja) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
CN113318125A (zh) * 2021-06-04 2021-08-31 青岛农业大学 一种紫锥菊多糖纳米颗粒的制备方法
FR3115683A1 (fr) * 2020-11-04 2022-05-06 Bobs Silver Composition antiseptique pour administration nasale
WO2022096605A1 (fr) * 2020-11-04 2022-05-12 Bobs Silver Composition antiseptique
FR3124378A1 (fr) * 2021-06-24 2022-12-30 Bobs Silver Composition antiseptique pour administration nasale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045537A2 (fr) * 2002-11-14 2004-06-03 Zengen, Inc. Film comestible servant au soulagement de la toux ou de symptomes associes a la pharyngite
WO2005120173A2 (fr) * 2004-05-12 2005-12-22 Kishore Madhukar Paknikar Activite antimicrobienne de nanoparticules d'argent stabilisees sur le plan biologique
WO2006079109A2 (fr) * 2005-01-21 2006-07-27 Rdx Technologies, Inc. Compositions antimicrobiennes non toxiques, et procedes d'utilisation de polyphenols pro-oxydatifs et d'antioxydants
US20070269576A1 (en) * 2006-05-18 2007-11-22 Brent Barton Exotic fruit juice and silver-containing beverage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045537A2 (fr) * 2002-11-14 2004-06-03 Zengen, Inc. Film comestible servant au soulagement de la toux ou de symptomes associes a la pharyngite
WO2005120173A2 (fr) * 2004-05-12 2005-12-22 Kishore Madhukar Paknikar Activite antimicrobienne de nanoparticules d'argent stabilisees sur le plan biologique
WO2006079109A2 (fr) * 2005-01-21 2006-07-27 Rdx Technologies, Inc. Compositions antimicrobiennes non toxiques, et procedes d'utilisation de polyphenols pro-oxydatifs et d'antioxydants
US20070269576A1 (en) * 2006-05-18 2007-11-22 Brent Barton Exotic fruit juice and silver-containing beverage

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920855B1 (en) * 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
CN105601861A (zh) * 2016-02-23 2016-05-25 同光（江苏）信息科技有限公司 一种有机硅改性水性聚氨酯树脂的合成方法
CN105601861B (zh) * 2016-02-23 2018-08-28 同光（江苏）信息科技有限公司 一种有机硅改性水性聚氨酯树脂的合成方法
JP2020512409A (ja) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP7113540B2 (ja) 2017-03-30 2022-08-05 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP2022153490A (ja) * 2017-03-30 2022-10-12 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP7411266B2 (ja) 2017-03-30 2024-01-11 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
FR3115683A1 (fr) * 2020-11-04 2022-05-06 Bobs Silver Composition antiseptique pour administration nasale
WO2022096605A1 (fr) * 2020-11-04 2022-05-12 Bobs Silver Composition antiseptique
CN113318125A (zh) * 2021-06-04 2021-08-31 青岛农业大学 一种紫锥菊多糖纳米颗粒的制备方法
FR3124378A1 (fr) * 2021-06-24 2022-12-30 Bobs Silver Composition antiseptique pour administration nasale

Similar Documents

Publication Publication Date Title
RU2553363C2 (ru) Антисептические композиции и их применения
EP2775838B1 (fr) Composition antimicrobienne aqueuse contenant des acides de résines de conifères
US20150264935A1 (en) Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same
CN105055642A (zh) 一种复方胍类消毒剂及其制备方法
JP2011522831A (ja) ナノシルバーを含むニキビ治療用組成物及びその使用
CN102085370B (zh) 一种口腔炎症性疾病的口腔喷剂及其制备方法
HU229230B1 (hu) Gyógyászati készítmény Herpes simplex vírus és más fertõzések okozta megbetegedések kezelésére
US20190008905A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
WO2008104076A1 (fr) Préparation antimicrobienne à base d'argent électro-colloïdal et de racine d'échinacée
KR20180051501A (ko) 과산화수소를 방출하는 항균 조성물 및 제제
US20100284951A1 (en) Novel compositions for the treatment of wounds and skin care
CA2425780C (fr) Composition a base d'un compose therapeutique actif, en particulier le miel, pour le traitement de blessures
AU2011296641B2 (en) Antifungal composition
CN114028546A (zh) 复合多肽杀菌制剂及其制备方法和用途
US20200405637A1 (en) Oil-based wound care compositions and methods
CN109432201B (zh) 妇科抗菌凝胶及其制备方法
CN106267329A (zh) 一种植物精油凝胶敷料及其制备方法和应用
KR102251911B1 (ko) 은 이온 항균 손세정제 및 그 제조 방법
CN108079050A (zh) 本草皮肤抑菌组合物及其制备方法与应用
CN103202881A (zh) 一种治疗皮疹的外用剂组合物
US20170027881A1 (en) Composition and related methods for treatment of pilosebaceous diseases
KR102115668B1 (ko) 프로바이오틱스 발효물을 포함하는 항여드름 활성을 갖는 화장료 조성물
CN106236835A (zh) 一种植物精油喷剂及其制备方法和应用
CN103230386A (zh) 一种免洗皮肤手微乳消毒液制剂及其制备方法
CN109045029A (zh) 一种咪唑并吡啶衍生物的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714704

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08714704

Country of ref document: EP

Kind code of ref document: A1